Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-125.17%
operating margin TTM
-98.4%
revenue TTM
10.44 Million
revenue per share TTM
0.05$
valuation ratios | |
|---|---|
| pe ratio | -17.98 |
| peg ratio | 1.97 |
| price to book ratio | -5.75 |
| price to sales ratio | 22.63 |
| enterprise value multiple | -17.44 |
| price fair value | -5.75 |
profitability ratios | |
|---|---|
| gross profit margin | 93.78% |
| operating profit margin | -98.4% |
| pretax profit margin | -126.2% |
| net profit margin | -125.17% |
| return on assets | -52.95% |
| return on equity | 36.0% |
| return on capital employed | -102.9% |
liquidity ratios | |
|---|---|
| current ratio | 1.44 |
| quick ratio | 1.40 |
| cash ratio | 1.08 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 333.83 |
| operating cycle | 462.99 |
| days of payables outstanding | 294.13 |
| cash conversion cycle | 168.86 |
| receivables turnover | 2.83 |
| payables turnover | 1.24 |
| inventory turnover | 1.09 |
debt and solvency ratios | |
|---|---|
| debt ratio | 2.47 |
| debt equity ratio | -1.49 |
| long term debt to capitalization | 5.29 |
| total debt to capitalization | 3.03 |
| interest coverage | -5.00 |
| cash flow to debt ratio | -0.13 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.33 |
| cash per share | 4.83 |
| operating cash flow per share | -2.28 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -0.13 |
| short term coverage ratios | -0.77 |
| capital expenditure coverage ratio | -43.67 |
Frequently Asked Questions
When was the last time BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported earnings?
BridgeBio Pharma, Inc. (BBIO) published its most recent earnings results on 07-05-2026.
What is BridgeBio Pharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. BridgeBio Pharma, Inc. (NASDAQ:BBIO)'s trailing twelve months ROE is 36.0%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. BridgeBio Pharma, Inc. (BBIO) currently has a ROA of -52.95%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did BBIO's net profit margin stand at?
BBIO reported a profit margin of -125.17% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is BBIO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.44 in the most recent quarter. The quick ratio stood at 1.40, with a Debt/Eq ratio of -1.49.